Probing the human hippocampus using rCBF: Contrasts in schizophrenia

Deborah R. Medoff, Henry H. Holcomb, Adrienne C. Lahti, Carol A. Tamminga

Research output: Contribution to journalArticle

157 Citations (Scopus)

Abstract

Regional cerebral blood flow (rCBF) data from two PET-15O water schizophrenia studies were analyzed using individually placed, magnetic resonance (MR)-guided hippocampal volumes of interest (VOI). In one study, normal (N = 10) and schizophrenic (N = 18) volunteers performed an overlearned auditory discrimination task in rest, control, and decision conditions. In the other study, schizophrenic and normal volunteers received the noncompetitive NMDA receptor antagonist ketamine and placebo and had sequential rCBF evaluations. Moreover, the schizophrenic volunteers were off drug in one study and on antipsychotic drug in the second study, allowing an additional comparison of medication status. VOIs were placed on anterior, middle, and posterior hippocampal areas in each PET image from both studies, redirected from an MR scan, and individually adjusted. While no hippocampal activation was apparent in either the normal or schizophrenic group in the task vs. condition comparison, rCBF was higher in the schizophrenic than in the normal hippocampus in both task and control conditions, independently. In addition, at rest rCBF was significantly higher in the unmedicated group of schizophrenics than in the group of medicated patient volunteers and higher than in the normal comparison group. This suggests that schizophrenia is associated with elevated rCBF in the hippocampus, which "normalizes" with antipsychotic drug treatment. Ketamine, the noncompetitive NMDA receptor antagonist, was more potent in reducing rCBF in the schizophrenic group compared to the normal volunteer group. These data are consistent with a previous report from our laboratory of reduced NMDA receptor NR1 subunit expression and possible abnormal NMDA receptor composition in schizophrenia. These data show an abnormality of hippocampal function in schizophrenia and suggest that this abnormality may be associated with the pathophysiology of the illness.

Original languageEnglish (US)
Pages (from-to)543-550
Number of pages8
JournalHippocampus
Volume11
Issue number5
DOIs
StatePublished - 2001

Fingerprint

Cerebrovascular Circulation
Regional Blood Flow
Hippocampus
Schizophrenia
N-Methyl-D-Aspartate Receptors
Volunteers
Ketamine
Antipsychotic Agents
Healthy Volunteers
Magnetic Resonance Spectroscopy
Placebos
Water

Keywords

  • Auditory discrimination
  • Hippocampus
  • Ketamine
  • rCBF
  • Schizophrenia

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Probing the human hippocampus using rCBF : Contrasts in schizophrenia. / Medoff, Deborah R.; Holcomb, Henry H.; Lahti, Adrienne C.; Tamminga, Carol A.

In: Hippocampus, Vol. 11, No. 5, 2001, p. 543-550.

Research output: Contribution to journalArticle

Medoff, Deborah R. ; Holcomb, Henry H. ; Lahti, Adrienne C. ; Tamminga, Carol A. / Probing the human hippocampus using rCBF : Contrasts in schizophrenia. In: Hippocampus. 2001 ; Vol. 11, No. 5. pp. 543-550.
@article{021394754bed4f869fedf19c1dc5838d,
title = "Probing the human hippocampus using rCBF: Contrasts in schizophrenia",
abstract = "Regional cerebral blood flow (rCBF) data from two PET-15O water schizophrenia studies were analyzed using individually placed, magnetic resonance (MR)-guided hippocampal volumes of interest (VOI). In one study, normal (N = 10) and schizophrenic (N = 18) volunteers performed an overlearned auditory discrimination task in rest, control, and decision conditions. In the other study, schizophrenic and normal volunteers received the noncompetitive NMDA receptor antagonist ketamine and placebo and had sequential rCBF evaluations. Moreover, the schizophrenic volunteers were off drug in one study and on antipsychotic drug in the second study, allowing an additional comparison of medication status. VOIs were placed on anterior, middle, and posterior hippocampal areas in each PET image from both studies, redirected from an MR scan, and individually adjusted. While no hippocampal activation was apparent in either the normal or schizophrenic group in the task vs. condition comparison, rCBF was higher in the schizophrenic than in the normal hippocampus in both task and control conditions, independently. In addition, at rest rCBF was significantly higher in the unmedicated group of schizophrenics than in the group of medicated patient volunteers and higher than in the normal comparison group. This suggests that schizophrenia is associated with elevated rCBF in the hippocampus, which {"}normalizes{"} with antipsychotic drug treatment. Ketamine, the noncompetitive NMDA receptor antagonist, was more potent in reducing rCBF in the schizophrenic group compared to the normal volunteer group. These data are consistent with a previous report from our laboratory of reduced NMDA receptor NR1 subunit expression and possible abnormal NMDA receptor composition in schizophrenia. These data show an abnormality of hippocampal function in schizophrenia and suggest that this abnormality may be associated with the pathophysiology of the illness.",
keywords = "Auditory discrimination, Hippocampus, Ketamine, rCBF, Schizophrenia",
author = "Medoff, {Deborah R.} and Holcomb, {Henry H.} and Lahti, {Adrienne C.} and Tamminga, {Carol A.}",
year = "2001",
doi = "10.1002/hipo.1070",
language = "English (US)",
volume = "11",
pages = "543--550",
journal = "Hippocampus",
issn = "1050-9631",
publisher = "Wiley-Liss Inc.",
number = "5",

}

TY - JOUR

T1 - Probing the human hippocampus using rCBF

T2 - Contrasts in schizophrenia

AU - Medoff, Deborah R.

AU - Holcomb, Henry H.

AU - Lahti, Adrienne C.

AU - Tamminga, Carol A.

PY - 2001

Y1 - 2001

N2 - Regional cerebral blood flow (rCBF) data from two PET-15O water schizophrenia studies were analyzed using individually placed, magnetic resonance (MR)-guided hippocampal volumes of interest (VOI). In one study, normal (N = 10) and schizophrenic (N = 18) volunteers performed an overlearned auditory discrimination task in rest, control, and decision conditions. In the other study, schizophrenic and normal volunteers received the noncompetitive NMDA receptor antagonist ketamine and placebo and had sequential rCBF evaluations. Moreover, the schizophrenic volunteers were off drug in one study and on antipsychotic drug in the second study, allowing an additional comparison of medication status. VOIs were placed on anterior, middle, and posterior hippocampal areas in each PET image from both studies, redirected from an MR scan, and individually adjusted. While no hippocampal activation was apparent in either the normal or schizophrenic group in the task vs. condition comparison, rCBF was higher in the schizophrenic than in the normal hippocampus in both task and control conditions, independently. In addition, at rest rCBF was significantly higher in the unmedicated group of schizophrenics than in the group of medicated patient volunteers and higher than in the normal comparison group. This suggests that schizophrenia is associated with elevated rCBF in the hippocampus, which "normalizes" with antipsychotic drug treatment. Ketamine, the noncompetitive NMDA receptor antagonist, was more potent in reducing rCBF in the schizophrenic group compared to the normal volunteer group. These data are consistent with a previous report from our laboratory of reduced NMDA receptor NR1 subunit expression and possible abnormal NMDA receptor composition in schizophrenia. These data show an abnormality of hippocampal function in schizophrenia and suggest that this abnormality may be associated with the pathophysiology of the illness.

AB - Regional cerebral blood flow (rCBF) data from two PET-15O water schizophrenia studies were analyzed using individually placed, magnetic resonance (MR)-guided hippocampal volumes of interest (VOI). In one study, normal (N = 10) and schizophrenic (N = 18) volunteers performed an overlearned auditory discrimination task in rest, control, and decision conditions. In the other study, schizophrenic and normal volunteers received the noncompetitive NMDA receptor antagonist ketamine and placebo and had sequential rCBF evaluations. Moreover, the schizophrenic volunteers were off drug in one study and on antipsychotic drug in the second study, allowing an additional comparison of medication status. VOIs were placed on anterior, middle, and posterior hippocampal areas in each PET image from both studies, redirected from an MR scan, and individually adjusted. While no hippocampal activation was apparent in either the normal or schizophrenic group in the task vs. condition comparison, rCBF was higher in the schizophrenic than in the normal hippocampus in both task and control conditions, independently. In addition, at rest rCBF was significantly higher in the unmedicated group of schizophrenics than in the group of medicated patient volunteers and higher than in the normal comparison group. This suggests that schizophrenia is associated with elevated rCBF in the hippocampus, which "normalizes" with antipsychotic drug treatment. Ketamine, the noncompetitive NMDA receptor antagonist, was more potent in reducing rCBF in the schizophrenic group compared to the normal volunteer group. These data are consistent with a previous report from our laboratory of reduced NMDA receptor NR1 subunit expression and possible abnormal NMDA receptor composition in schizophrenia. These data show an abnormality of hippocampal function in schizophrenia and suggest that this abnormality may be associated with the pathophysiology of the illness.

KW - Auditory discrimination

KW - Hippocampus

KW - Ketamine

KW - rCBF

KW - Schizophrenia

UR - http://www.scopus.com/inward/record.url?scp=0035189584&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035189584&partnerID=8YFLogxK

U2 - 10.1002/hipo.1070

DO - 10.1002/hipo.1070

M3 - Article

C2 - 11732707

AN - SCOPUS:0035189584

VL - 11

SP - 543

EP - 550

JO - Hippocampus

JF - Hippocampus

SN - 1050-9631

IS - 5

ER -